Immunotherapy in Hepatocellular Carcinoma: Improving the Treatment Paradigm Within Community Practice

The goal of this program is to improve the knowledge and competence of learners to individualize the therapeutic management of patients with hepatocellular carcinoma (HCC).

Provided by the National Comprehensive Cancer Network in partnership with Clinical Care Options, LLC

Target Audience

This educational program is intended for medical oncologists, surgical oncologists, pathologists, PAs, nurses, pharmacists, and other HCPs who treat patients with HCC.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply guideline and expert recommendations for surveillance of patients at risk of developing HCC, including the clinical application of biomarker-based surveillance 
  • Integrate clinical data and guideline recommendations on the use of systemic treatment approaches into practice for patients with early-stage or intermediate-stage HCC
  • Plan evidence-based and guideline-driven individualized care for patients with advanced HCC 
  • Identify patients with HCC who may benefit from ongoing clinical trials investigating ICI-based therapies 

You may also be interested in

Clinical Scenario #5: Applying Biomarkers in Biliary Tract Cancers
To provide optimal patient care, clinicians need to be well informed about the factors affecting the selection of the appropriate tests, the nuances of analyzing and interpreting complex test results in order to select the most appropriate treatment for their patients, and how to communicate with patients about the results.
NCCN Guidelines® Insights - Biliary Tract Cancers, Version 2.2023
The NCCN Guidelines for Biliary Tract Cancers provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. These Guidelines Insights focus on some of the recent updates to the NCCN Guidelines for Biliary Tract Cancers as well as the newly published section on principles of molecular testing.
Additional information
Supporters: 

Supported by an educational grant from AstraZeneca.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation
Course opens: 
12/19/2023
Course expires: 
12/19/2024
Cost:
$0.00

Katie Kelley, MD
Professor of Clinical Medicine
School of Medicine
University of California
San Francisco, California

 

NCCN Continuing Education Disclosure Policy
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions  

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers  

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have the following relevant financial relationships with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Katie Kelley, MD
Agios, Inc.: Grant/Research Support
AstraZeneca Pharmaceuticals LP: Grant/Research Support 
Bayer HealthCare: Grant/Research Support
Bristol-Myers Squibb Company: Grant/Research Support 
Compass: Consultant/Advisor/Speaker
Eli Lilly and Company: Grant/Research Support
EMD Serono: Grant/Research Support
Exelixis Inc.: Grant/Research Support
Genentech/Roche: Grant/Research Support
J Pharma: Consultant/Advisor/Speaker
Kinnate: Consultant/Advisor/Speaker
Loxo Oncology: Grant/Research Support
Merck & Co., Inc.: Grant/Research Support
Partner Therapeutics, Inc.: Grant/Research Support
QED Therapeutics: Grant/Research Support 
Regeneron Pharmaceuticals, Inc.: Consultant/Advisor/Speaker
Relay Therapeutics: Grant/Research Support 
Servier: Grant/Research Support
Surface Oncology, Inc.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Grant/Research Support
Tyra Biosciences: Consultant/Advisor/Speaker

NCCN and CCO Staff Disclosures

None of the other planners/managers for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.1 CEUs) of continuing education credit. UAN: JA4008196-0000-23-133-H01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. Approval is valid until December 19, 2024. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
  • 1.00 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing